Exon 25 was replaced with one in which a point mutation that results in the amino acid substitution of glutamine for arginine at position 1279. This mutation corresponds to the R1275 identified in patients with neuroblastoma. Cre-mediated recombination removed the neomycin resistance cassette inserted downstream of the modified exon. (J:228124)